In-licensing is an important mechanism by which NMI is building a diversified product pipeline. We continue to search for and evaluate highly specific / targeted therapeutic opportunities which may complement our existing pipeline. In addition to compounds with attractive intrinsic properties, NMI is particularly interested in candidate therapies for which the application of our molecularly targeted technology platform could offer the potential to derive unique insights into patient selection that may help inform clinical development and create differentiation from competitors.
We also remain committed to accessing the best technologies and tools to support our research and development efforts through collaborations and licenses. To supplement our own molecular targeted technology and capabilities, NMI has entered into various collaborations agreements in order to access advanced tools for drug discovery.
The DNA of a cancer cell encodes about 22,000 genes that generate over 250,000 unique RNA molecules that perpetuate cancer in over 70% of patients with cancer who lack "actionable" DNA mutations. At Nemucore Medical Innovations Inc we strive to understand the language of RNA, which is a critical step in unlocking the knowledge to develop and commercialize novel life saving precision medicines for the benefit of patients with cancer.